Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 139

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 139
---
 registration statement, of which this
prospectus forms a part.

The selling stockholders and
any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations
thereunder, including, without limitation, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any
of the Common Shares by the selling stockholders and any other participating person. Regulation M may also restrict the ability of any
person engaged in the distribution of the Common Shares to engage in market-making activities with respect to the Common Shares. All of
the foregoing may affect the marketability of the Common Shares and the ability of any person or entity to engage in market-making activities
with respect to the Common Shares.

We will pay all expenses
of the registration of the Common Shares pursuant to the Registration Rights Agreement, estimated to be $[___] in total, including, without
limitation, SEC filing fees and expenses of compliance with state securities or “blue sky” laws; provided, however, that
a selling stockholder will pay all underwriting discounts and selling commissions, if any. We will indemnify the selling stockholders
against liabilities, including some liabilities under the Securities Act, in accordance with the Registration Rights Agreement, or the
selling stockholders will be entitled to contribution. We may be indemnified by the selling stockholders against civil liabilities, including
liabilities under the Securities Act, that may arise from any written information furnished to us by the selling stockholder specifically
for use in this prospectus, in accordance with the Registration Rights Agreement, or we may be entitled to contribution.

Once sold under the registration
statement, of which this prospectus forms a part, the Common Shares will be freely tradable in the hands of persons other than our affiliates.

Exhibit 99.3

<div align='center'>COMMON SHARES PURCHASE AGREEMENT</div>

This COMMON SHARES PURCHASE AGREEMENT is made and entered into as of March 28, 2025 (this “Agreement”), by and between Alpha Capital
Anstalt, a Liechtenstein Anstalt (the “Investor”), and NLS Pharmaceutics Ltd., a corporation incorporated under
the laws of Switzerland (the “Company”).

<div align='center'>RECITALS</div>

WHEREAS, the parties
desire that, upon the terms and subject to the conditions and limitations set forth herein, the Company may issue and sell to the Investor,
from time to time as